{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:27:00Z","timestamp":1788715620234,"version":"build-2803163510"},"reference-count":32,"publisher":"IOP Publishing","issue":"2","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"},{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/iopscience.iop.org\/info\/page\/text-and-data-mining"}],"content-domain":{"domain":["iopscience.iop.org"],"crossmark-restriction":false},"short-container-title":["J. Breath Res."],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic obstructive pulmonary disease (COPD) is a heterogeneous inflammatory lung disease. It is important to identify patients who would respond to anti-inflammatory treatment. This prospective study aims to determine how inflammatory biomarkers could be used to predict the potential effect of inhaled corticosteroids (ICS) in terms of symptoms and lung function. We evaluated the levels of blood eosinophils, exhaled nitric oxide fraction at a flow rate of 50 ml s<jats:sup>\u22121<\/jats:sup> (FeNO), alveolar nitric oxide concentration (Calv), immunoglobulin E and atopy in 43 patients with symptomatic COPD and correlated these expression levels with the changes in the COPD Assessment Test (CAT) and lung function by 12 weeks of add-on therapy with ciclesonide 400 <jats:italic>\u03bc<\/jats:italic>g d<jats:sup>\u22121<\/jats:sup> on bronchodilators. The mean changes in the CAT score and FEV<jats:sub>1<\/jats:sub> were \u22121.4 points and +90 ml, respectively, with significant variation in the levels of change. The area under the receiver\u2019s operating characteristic curve (AUC) for FeNO in predicting improvements in both the CAT score and FEV<jats:sub>1<\/jats:sub> was 0.92. The AUC for Calv and blood eosinophils was 0.82 and 0.65. Two cutoffs were chosen, one corresponding to a high value of FeNO associated with certainty for response inclusion (FeNO\u00a0=\u00a035 ppb; sensitivity\u00a0=\u00a00.67, specificity\u00a0=\u00a00.94; positive predictive value\u00a0=\u00a00.80) and the other with certainty for response exclusion (FeNO\u00a0=\u00a020 ppb; sensitivity\u00a0=\u00a01.00, specificity\u00a0=\u00a00.58, negative predictive value\u00a0=\u00a01.00). Baseline FeNO values were significantly correlated with changes in FEV<jats:sub>1<\/jats:sub> and CAT (all <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.0001). FeNO could be a valuable biomarker for identifying individuals who respond to steroid therapy among patients with symptomatic COPD in terms of symptoms and airflow limitation. The study was prospectively registered with the University Hospital Medical Information Network (UMIN) in Japan (protocol ID 000010711).<\/jats:p>","DOI":"10.1088\/1752-7163\/ab71a4","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T22:15:20Z","timestamp":1580422520000},"page":"026007","update-policy":"https:\/\/doi.org\/10.1088\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Detection of type2 biomarkers for response in COPD"],"prefix":"10.1088","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2847-3702","authenticated-orcid":false,"given":"Yoshikazu","family":"Yamaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-0450","authenticated-orcid":false,"given":"Keiji","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ohteru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Chikumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Murakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Suetake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoriyuki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Asami-Noyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Edakuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunahiko","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"266","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"jbrab71a4bib1","author":"","year":"2019"},{"key":"jbrab71a4bib2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1164\/ajrccm.161.2.16125_1","article-title":"Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease","volume":"161","author":"Calverley","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"jbrab71a4bib3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1164\/ajrccm.161.2.16125_2","article-title":"Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease","volume":"161","author":"Barnes","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"jbrab71a4bib4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1164\/ajrccm.155.2.9032177","article-title":"Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects","volume":"155","author":"Keatings","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"jbrab71a4bib5","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2008.717","article-title":"Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"300","author":"Drummond","year":"2008","journal-title":"JAMA"},{"key":"jbrab71a4bib6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1183\/09031936.00193908","article-title":"Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results","volume":"34","author":"Crim","year":"2009","journal-title":"Eur. Respir. J."},{"key":"jbrab71a4bib7","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1378\/chest.130.4.1082","article-title":"Use of inhaled corticosteroids and the risk of fracture","volume":"130","author":"Hubbard","year":"2006","journal-title":"Chest"},{"key":"jbrab71a4bib8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1164\/rccm.201408-1458OC","article-title":"Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease","volume":"191","author":"Christenson","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"jbrab71a4bib9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/thx.2004.032516","article-title":"Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease","volume":"60","author":"Brightling","year":"2005","journal-title":"Thorax"},{"key":"jbrab71a4bib10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.rmed.2004.12.008","article-title":"The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease","volume":"99","author":"Zietkowski","year":"2005","journal-title":"Respir. Med."},{"key":"jbrab71a4bib11","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1183\/09031936.06.00072105","article-title":"Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment","volume":"27","author":"Leigh","year":"2006","journal-title":"Eur. Respir. J."},{"key":"jbrab71a4bib12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1164\/rccm.200905-0685OC","article-title":"Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide","volume":"180","author":"Dummer","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"jbrab71a4bib13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1183\/09031936.00177508","article-title":"Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD","volume":"35","author":"Lehtimaki","year":"2010","journal-title":"Eur. Respir. J."},{"key":"jbrab71a4bib14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fphar.2011.00036","article-title":"Improvement of airflow limitation by fluticasone propionate\/salmeterol in chronic obstructive pulmonary disease: what is the specific marker?","volume":"2","author":"Akamatsu","year":"2011","journal-title":"Front. Pharmacol."},{"key":"jbrab71a4bib15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting beta-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"key":"jbrab71a4bib16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2332\/allergolint.10-OA-0277","article-title":"Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects","volume":"60","author":"Matsunaga","year":"2011","journal-title":"Allergol. Int."},{"key":"jbrab71a4bib17","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"jbrab71a4bib18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1152\/jappl.1998.85.2.653","article-title":"A two-compartment model of pulmonary nitric oxide exchange dynamics","volume":"85","author":"Tsoukias","year":"1998","journal-title":"J. Appl. Physiol."},{"key":"jbrab71a4bib19","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD assessment test","volume":"34","author":"Jones","year":"2009","journal-title":"Eur. Respir. J."},{"key":"jbrab71a4bib20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S2213-2600(14)70001-3","article-title":"Minimum clinically important difference for the COPD assessment test: a prospective analysis","volume":"2","author":"Kon","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"jbrab71a4bib21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"jbrab71a4bib22","author":"","year":"2015"},{"key":"jbrab71a4bib23","doi-asserted-by":"publisher","first-page":"1800616","DOI":"10.1183\/13993003.00616-2018","article-title":"Combined value of exhaled nitric oxide and blood eosinophils in chronic airway disease: the copenhagen general population study","volume":"52","author":"Colak","year":"2018","journal-title":"Eur. Respir. J."},{"key":"jbrab71a4bib24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.alit.2018.01.002","article-title":"Definition and diagnosis of asthma-COPD overlap (ACO)","volume":"67","author":"Yanagisawa","year":"2018","journal-title":"Allergol. Int."},{"key":"jbrab71a4bib25","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1440-1843.2010.01711.x","article-title":"Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations","volume":"15","author":"Antus","year":"2010","journal-title":"Respirology"},{"key":"jbrab71a4bib26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02397-2016","article-title":"Th-2 signature in chronic airway diseases: towards the extinction of asthma-COPD overlap syndrome?","volume":"49","author":"Cosio","year":"2017","journal-title":"Eur. Respir. J."},{"key":"jbrab71a4bib27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2332\/allergolint.10-OA-0197","article-title":"Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population","volume":"59","author":"Matsunaga","year":"2010","journal-title":"Allergol. Int."},{"key":"jbrab71a4bib28","doi-asserted-by":"publisher","DOI":"10.1088\/1752-7163\/aaa4c5","article-title":"Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease","volume":"12","author":"Pizzini","year":"2018","journal-title":"J. Breath Res."},{"key":"jbrab71a4bib29","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1164\/rccm.201811-2210OC","article-title":"Exhaled volatile organic compounds are able to discriminate between neutrophilic and eosinophilic asthma","volume":"200","author":"Schleich","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"jbrab71a4bib30","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.2147\/COPD.S181938","article-title":"Characteristics of 2017 GOLD COPD group a: a multicenter cross-sectional CAP study in Japan","volume":"13","author":"Oishi","year":"2018","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"jbrab71a4bib31","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","article-title":"Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"jbrab71a4bib32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/thorax.58.8.654","article-title":"Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study","volume":"58","author":"Burge","year":"2003","journal-title":"Thorax"}],"container-title":["Journal of Breath Research"],"original-title":[],"link":[{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4","content-type":"text\/html","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4","content-type":"text\/html","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T20:10:08Z","timestamp":1637784608000},"score":1,"resource":{"primary":{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1752-7163\/ab71a4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,25]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1088\/1752-7163\/ab71a4","relation":{},"ISSN":["1752-7155","1752-7163"],"issn-type":[{"value":"1752-7155","type":"print"},{"value":"1752-7163","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"Detection of type2 biomarkers for response in COPD","name":"article_title","label":"Article Title"},{"value":"Journal of Breath Research","name":"journal_title","label":"Journal Title"},{"value":"paper","name":"article_type","label":"Article Type"},{"value":"\u00a9 2020 The Author(s). Published by IOP Publishing Ltd","name":"copyright_information","label":"Copyright Information"},{"value":"2019-12-15","name":"date_received","label":"Date Received","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2020-01-30","name":"date_accepted","label":"Date Accepted","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2020-02-25","name":"date_epub","label":"Online publication date","group":{"name":"publication_dates","label":"Publication dates"}}]}}